NCT00737633 - Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions

Diabetes

Interventions

DRUG

VI-0521

Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks

Trial Locations (9)

Research Site, Birmingham

Research Site, Los Angeles

Research Site, San Francisco

Research Site, Spring Valley

Research Site, Walnut Creek

Research Site, Bethesda

Research Site, Austin

Research Site, San Antonio

Research Site, Richmond